Scleroderma Diagnostics and Therapeutics Market Share [2031]

Scleroderma Diagnostics and Therapeutics Market Share [2031]

Segments - Scleroderma Diagnostics and Therapeutics Market by Disease Type (Systemic Scleroderma [Limited Scleroderma and Diffused Scleroderma] and Localized Scleroderma [Linear Scleroderma and Morphea]), Test Type (Antibodies Test [Anti-U3, Anti-SCL70, and Anticentromere Antibodies], Urinalysis, Thyroid Function, Metabolic Panel, Muscle Enzymes, and Complete Blood Count), Drug Type (Alpha Blockers, Calcium Channel Blockers, Serotonin Receptor Antagonists, Local Nitrates, Angiotensin II Receptor Inhibitors, Statins, and Others [Antibiotics, Azathioprine, Prostanoids, Tetracycline, Prokinetics, and Cyclophosphamide]), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-2573 | 4.5 Rating | 67 Reviews | 219 Pages | Format : PDF Excel PPT

Report Description


Scleroderma Diagnostics and Therapeutics Market Outlook 2031:

The global scleroderma diagnostics and therapeutics market size was valued at USD 1.91 Billion in 2022 and is projected to reach USD 3.23 Billion by 2031, expanding at a CAGR of 6% during the forecast period 2023 - 2031The growth of the market is attributed to the rising incidence of scleroderma cases and the increasing prevalence of genetic mutations along with the occurrence of extreme changes in the environment.

An autoimmune disease that affects the skin, muscles, blood vessels, and internal organs is known as scleroderma. The skin and connective tissues start to tighten & harden when a person is affected with such disorder. It is caused due to an immune response that is abnormal. Scleroderma occurs when collagen is overproduced in an individual’s body.

Scleroderma Diagnostics and Therapeutics Market Outlook


however, the actual reason for the occurrence of scleroderma is not known. Scleroderma is a long-term and rare disease that affects women more than men. It mostly occurs between the ages of 30 to 50. The occurrence of scleroderma is likely four times more in women than in men.  Currently, no drug is available and approved for the treatment of scleroderma.

Approximately 2.5 million individuals are affected with scleroderma globally, which makes it a chronic disease. The report by Scleroderma & Raynaud’s UK stated that in 2018 about 19,000 individuals were diagnosed with scleroderma in the UK. The organization has been focusing on offering charity and continuously working for the betterment of those individuals who are suffering from scleroderma. As per the internal reports from Britain and Japan, the occurrence of scleroderma in adults is approximately 35 in 1 million.

  • Increasing levels of awareness among patients regarding healthcare coupled with the growing disposable income of the population are anticipated to fuel the market growth during the forecast period.
  • Presence of medical needs and presence of highly unmet patients along with the introduction of new products are expected to propel the market growth during the forecast period.
  • Growing focus of several pharmaceutical companies in order to develop novel drugs is anticipated to drive market expansion in the coming years.
  • Issues related to reimbursement policy and stringent regulatory policies are key challenges that can restrain the market growth during the forecast period.
  • Ongoing research & development programs and expansion of clinical experiments in the field of scleroderma diagnostics & therapeutics are projected to create lucrative opportunities for market growth.

 Scope of Scleroderma Diagnostics and Therapeutics Market Report

The market report includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Scleroderma Diagnostics and Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Disease Type (Systemic Scleroderma [Limited Scleroderma and Diffused Scleroderma] and Localized Scleroderma [Linear Scleroderma and Morphea]), Test Type (Antibodies Test [Anti-U3, Anti-SCL70, and Anticentromere Antibodies], Urinalysis, Thyroid Function, Metabolic Panel, Muscle Enzymes, and Complete Blood Count), and Drug Type (Alpha Blockers, Calcium Channel Blockers, Serotonin Receptor Antagonists, Local Nitrates, Angiotensin II Receptor Inhibitors, Statins, and Others [Antibiotics, Azathioprine, Prostanoids, Tetracycline, Prokinetics, and Cyclophosphamide])

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

GlaxoSmithKline PLC; Angion Biomedica Corp.; BioLineRx, Ltd.; Allergan, Inc.; Bayer AG; Corbus pharmaceuticals, Inc.; Bristol-Myers Squibb Co.;  Digna Biotech; F. Hoffmann-La Roche Ltd.; Dynavax Technologies Corp.; Daval International Ltd.;  Active Biotech AB;  Fibrocell Science, Inc.; MedImmune; LLCVida Therapeutics Inc.; NovaLead Pharma Pvt. Ltd.; iBio, Inc.;  and VivaCell Biotechnology Espana S.L.

Scleroderma Diagnostics and Therapeutics Market Segment Insights     

On the basis of disease type, the global scleroderma diagnostics and therapeutics market is bifurcated into systemic scleroderma and localized scleroderma. The systemic scleroderma segment is further divided into limited scleroderma and diffused scleroderma. The localized scleroderma segment is further divided into linear scleroderma and morphea.

The systemic scleroderma segment is projected to account for a key market share during the projected period, owing to the rising prevalence of the disease and increasing demand for scleroderma therapeutics.

Scleroderma Diagnostics and Therapeutics Market Disease Type

Based on test type, the market is segmented into antibodies test, urinalysis, thyroid function, metabolic panel, muscle enzymes, and complete blood count. The antibodies segment is further divided into anti-U3, anti-SCL70, and anticentromere antibodies. The antibodies segment is anticipated to exhibit a high CAGR during the forecast period, owing to the easy availability of the test type and most common form of type for the diagnostic of the disease.

Scleroderma Diagnostics and Therapeutics Market Test Type

On the basis of drug type, the global scleroderma diagnostics and therapeutics market is categorized as alpha blockers, calcium channel blockers, serotonin receptor antagonists, local nitrates, angiotensin II receptor inhibitors, statins, and others. The others segment is further divided into antibiotics, azathioprine, prostanoids, tetracycline, prokinetics, and cyclophosphamide. The calcium channel blockers segment is expected to expand at a robust growth rate during the forecast period, owing to wide demand for the drug types.

In terms of region, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the projection period, due to the high funding by governments and the presence of favorable regulations for the development of the therapy in the region. The development of new products along with the ongoing trials on a large scale to enhance efficiency is expected to further boost the regional market growth.

However, the market of Asia Pacific is anticipated to expand at a rapid pace in the coming years, owing to the presence of unmet patient needs and the high prevalence of the disorder in the region.

Scleroderma Diagnostics and Therapeutics Market Region

Segments

The global scleroderma diagnostics and therapeutics market has been segmented on the basis of

Disease Type

  • Systemic Scleroderma
    • Limited Scleroderma
    • Diffused Scleroderma
  • Localized Scleroderma
    • Linear Scleroderma
    • Morphea

Test Type

  • Antibodies Test
    • Anti-U3
    • Anti-SCL70
    • Anticentromere Antibodies
  • Urinalysis
  • Thyroid Function
  • Metabolic Panel
  • Muscle Enzymes
  • Complete Blood Count

Drug Type

  • Alpha Blockers
  • Calcium Channel Blockers
  • Serotonin Receptor Antagonists
  • Local Nitrates
  • Angiotensin II Receptor Inhibitors
  • Statins
  • Others
    • Antibiotics
    • Azathiprine
    • Prostanoids
    • Tetracycline
    • Prokinetics
    • Cyclophosphamide

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • GSK plc
  • Angion Biomedica Corp.
  • BioLineRx, Ltd.
  • Allergan, Inc.
  • Bayer AG
  • Corbus pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co.
  • Digna Biotech
  • F. Hoffmann-La Roche Ltd.
  • Dynavax Technologies Corp.
  • Daval International Ltd.;
  • Active Biotech AB;
  • Fibrocell Science, Inc.
  • MedImmune
  • LLCVida Therapeutics Inc.
  • NovaLead Pharma Pvt. Ltd.
  • iBio, Inc.
  • VivaCell Biotechnology Espana S.L.

Competitive Landscape

Key players competing in the global scleroderma diagnostics and therapeutics market are GlaxoSmithKline PLC; Angion Biomedica Corp.; BioLineRx, Ltd.; Allergan, Inc.; Bayer AG; Corbus pharmaceuticals, Inc.; Bristol-Myers Squibb Co.; Digna Biotech; F. Hoffmann-La Roche Ltd.; Dynavax Technologies Corp.; Daval International Ltd.; Active Biotech AB; Fibrocell Science, Inc.; MedImmune; LLCVida Therapeutics Inc.; NovaLead Pharma Pvt. Ltd.; iBio, Inc.; and VivaCell Biotechnology Espana S.L.

Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion to increase their consumer base and expand their market position globally.

Scleroderma Diagnostics and Therapeutics Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Scleroderma Diagnostics and Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Scleroderma Diagnostics and Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Scleroderma Diagnostics and Therapeutics Market - Supply Chain
  4.5. Global Scleroderma Diagnostics and Therapeutics Market Forecast
     4.5.1. Scleroderma Diagnostics and Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Scleroderma Diagnostics and Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Scleroderma Diagnostics and Therapeutics Market Absolute $ Opportunity
5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
6. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
8. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Scleroderma Diagnostics and Therapeutics Market: Market Share Analysis
  11.2. Scleroderma Diagnostics and Therapeutics Distributors and Customers
  11.3. Scleroderma Diagnostics and Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Methodology

Our Clients

sinopec
Deloitte
The John Holland Group
Microsoft
General Electric
Siemens Healthcare
Dassault Aviation
FedEx Logistics